Y
Yu Han Huang
Researcher at Taipei Medical University
Publications - 10
Citations - 1020
Yu Han Huang is an academic researcher from Taipei Medical University. The author has contributed to research in topics: Survivin & Angiogenesis. The author has an hindex of 9, co-authored 10 publications receiving 622 citations. Previous affiliations of Yu Han Huang include Harvard University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Jinfang Zhang,Xia Bu,Haizhen Wang,Yasheng Zhu,Yan Geng,Naoe Taira Nihira,Yuyong Tan,Yuyong Tan,Yanpeng Ci,Yanpeng Ci,Fei Wu,Fei Wu,Xiangpeng Dai,Jianping Guo,Yu Han Huang,Caoqi Fan,Caoqi Fan,Shancheng Ren,Yinghao Sun,Gordon J. Freeman,Piotr Sicinski,Wenyi Wei +21 more
TL;DR: It is shown that PD-L1 protein abundance is regulated by cyclin D–CDK4 and the cullin 3–SPOP E3 ligase via proteasome-mediated degradation, which reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1–PD-L 1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Journal ArticleDOI
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Yang Gao,Yang Gao,Naoe Taira Nihira,Naoe Taira Nihira,Naoe Taira Nihira,Xia Bu,Chen Chu,Jinfang Zhang,Aleksandra Kolodziejczyk,Yizeng Fan,Yizeng Fan,Ngai Ting Chan,Leina Ma,Jing Liu,Dong Wang,Xiaoming Dai,Huadong Liu,Masaya Ono,Akira Nakanishi,Hiroyuki Inuzuka,Brian J. North,Yu Han Huang,Samanta Sharma,Yan Geng,Wei Xu,X. Shirley Liu,Lei Li,Yoshio Miki,Piotr Sicinski,Gordon J. Freeman,Wenyi Wei +30 more
TL;DR: It is reported that PD-L1 translocates from the plasma membrane into the nucleus through interactions with components of the endocytosis and nucleocytoplasmic transport pathways, regulated by p300-mediated acetylation and HDAC2-dependent deacetylation of PD- L1.
Journal ArticleDOI
Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Jinfang Zhang,Xia Bu,Haizhen Wang,Yasheng Zhu,Yan Geng,Naoe Taira Nihira,Yuyong Tan,Yuyong Tan,Yanpeng Ci,Yanpeng Ci,Fei Wu,Fei Wu,Xiangpeng Dai,Jianping Guo,Yu Han Huang,Caoqi Fan,Caoqi Fan,Shancheng Ren,Yinghao Sun,Gordon J. Freeman,Piotr Sicinski,Wenyi Wei +21 more
TL;DR: An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
Journal ArticleDOI
Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade.
Hang Lung Chang,Chih Yu Chen,Ya Fen Hsu,Wen Shin Kuo,George Ou,Pei Ting Chiu,Yu Han Huang,Ming Jen Hsu +7 more
TL;DR: This study delineates the underlying mechanisms of simvastatin in decreasing survivin and subsequent colorectal cancer cell apoptosis and identifies a potential molecular target in cancer management.
Journal ArticleDOI
Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells
Ya Fen Hsu,Joen Rong Sheu,Chien-Huang Lin,De Shin Yang,George Hsiao,George Ou,Pei Ting Chiu,Yu Han Huang,Wen Hsin Kuo,Ming Jen Hsu +9 more
TL;DR: A p38MAPK- and AMPK-mediated downregulation of survivin is reported, and its functional correlation with decreased colon cancer cell viability in the presence of HDAC inhibitor is reported.